Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of palbociclib + exemestane + GnRH agonist versus capecitabine in premenopausal HR-positive metastatic breast cancer
KCT0003346Phase 2Recruiting
- Sponsor
- Pfizer Pharmacueticals Korea, Shin Poong Pharm, Daewoong Research&Development Center
- Start
- Jun 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib, exemestane, capecitabine in breast cancer, sponsored by Pfizer Pharmacueticals Korea, Shin Poong Pharm, Daewoong Research&Development Center. Started Jun 2016; status: recruiting.
02
Drugs
palbociclibexemestanecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0003346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003346.